Literature DB >> 27573149

[Even guidelines must be allowed to be questioned].

Y Kulu1, T Hackert1, J Debus2, M-A Weber3, M W Büchler1, A Ulrich4.   

Abstract

Year:  2016        PMID： 27573149     DOI： 10.1007/s00104-016-0280-4

Source DB:  PubMed          Journal:  Chirurg        ISSN： 0009-4722            Impact factor:   0.955


× No keyword cloud information.
  15 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.

Authors:  Morten T Eriksen; Arne Wibe; Jon Haffner; Johan N Wiig
Journal:  Dis Colon Rectum       Date:  2007-02       Impact factor: 4.585

3.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

4.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

Authors:  Willem van Gijn; Corrie A M Marijnen; Iris D Nagtegaal; Elma Meershoek-Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm J T Rutten; Lars Påhlman; Bengt Glimelius; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2011-05-17       Impact factor: 41.316

5.  Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.

Authors:  Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan Moran; Lennart Blomqvist; Ian Swift; David J Sebag-Montefiore; Paris Tekkis; Gina Brown
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

6.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

Authors:  Samuel Y Ngan; Bryan Burmeister; Richard J Fisher; Michael Solomon; David Goldstein; David Joseph; Stephen P Ackland; David Schache; Bev McClure; Sue-Anne McLachlan; Joseph McKendrick; Trevor Leong; Cris Hartopeanu; John Zalcberg; John Mackay
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

7.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

8.  Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.

Authors:  Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan J Moran; Lennart Blomqvist; Ian R Swift; David Sebag-Montefiore; Paris Tekkis; Gina Brown
Journal:  J Clin Oncol       Date:  2013-11-25       Impact factor: 44.544

9.  Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy.

Authors:  M Simunovic; R Sexton; E Rempel; B J Moran; R J Heald
Journal:  Br J Surg       Date:  2003-08       Impact factor: 6.939

10.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.